祐森健恒生物医药

U-SENSE Biopharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of novel small molecule and biologic drugs. The company focuses on therapeutic areas with high unmet needs, including metabolic diseases, oncology, and inflammation. Its lead candidate, UA007, is a potent URAT1 inhibitor currently undergoing Phase 2 clinical trials for the treatment of hyperuricemia and gout. Additionally, U-SENSE is advancing a pipeline of Toll-like receptor (TLR) modulators, including TLR8 agonists for cancer immunotherapy and TLR8 antagonists for autoimmune conditions. The company is supported by prominent venture capital firms and utilizes a robust internal R&D platform to accelerate drug development.